Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer

A Phase II Trial of Two Doses of Conjugated Estrogens (Premarin) in Patients With Androgen-Independent Prostate Cancer

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00134654

Enrollment

Registered

2005-08-25

Start date

2003-03-31

Completion date

2011-06-30

Last updated

2011-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

Androgen-independent prostate cancer, Premarin, conjugated estrogen

Brief summary

The purpose of this study is to see if Premarin is useful against androgen-independent prostate cancer and to help understand how drugs such as Premarin may work.

Detailed description

Patients will be randomly assigned to one of two study groups (arm A or Arm B). Arm A will receive 1.25mg of Premarin once daily and arm B will receive 1.25mg of Premarin three times a day. Patients will also receive coumadin daily to help prevent thromboembolic disease. After reviewing the first 30 patients on Arm A, it was determined that arm A (low dose Premarin) was not effective. Arm A was then closed and patients on Arm A were given the choice to switch to Arm B. Treatment will continue until there is evidence of disease progression or unacceptable side effects. Every 4 weeks while receiving Premarin, a physical exam and blood work will be performed. Every 12 weeks a CT scan of the abdomen and pelvis and a bone scan will be performed. Patients will also be encouraged to undergo standard preventative breast irradiation prior to starting Premarin or up to 4 weeks after starting treatment.

Interventions

DRUGPremarin

Group A: 1.25mg once a day Group B: 1.25mg three time a day Group A has been closed and participants have been given the option of enrolling in Group B. Treamtment can continue until disease progression or serious side effects.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Documented histologic evidence of prostate cancer. * Progressive androgen-independent prostate cancer as defined by the Prostate-Specific Antigen (PSA) Working Group after conventional androgen deprivation and antiandrogen withdrawal. * PSA \> 2ng/ml and serum testosterone of \< 50ng/ml * No history of thromboembolic disease within the prior year * ECOG performance status of 0-2 * Creatinine \< 2 x upper limit of normal * Bilirubin \< 2 x upper limit of normal * AST \< 2 x upper limit of normal

Exclusion criteria

* Unstable angina or change in anginal symptoms within the past 6 months. * Prior therapy with estrogens or PC-SPECS. * Concurrent megestrol acetate or steroid hormones * Major surgery or radiation therapy within 4 weeks * Strontium-89 or samarium-153 therapy within 8 weeks

Design outcomes

Primary

Measure	Time frame
To evaluate the efficacy of two different doses of Premarin in the treatment of patients with androgen-independent prostate cancer	—

Secondary

Measure	Time frame
To evaluate the safety of Premarin in this patient population	2 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026